CURRENT APPROACHES TO THERAPY OF KELOID SCARS: OPPORTUNITIES AND PROSPECTS OF THE USE OF TRAUMEEL S FROM THE POINT OF VIEW OF EVIDENCE-BASED MEDICINE

A prospective, randomized, open, controlled, comparative, parallel-group study evaluated the feasibility of an additional use of Traumeel S for the treatment of keloid scars. The study included 51 patients: 26 patients in the control group received conventional treatment (Kenalog 40 2-3 injections into the scar, once a month), and 25 patients of the main group received Traumeel S injections in addition to conventional treatment. Features of study included calculation of quantitative effects of intervention. Clinical evaluation and the results of in vitro studies carried out on primary cultures of human dermal fibroblasts indicate the advisability of the additional appointment of Traumeel S in the treatment of keloid scars.

keloid scars, evidence-based medicine, Traumeel S, Kenalog 40